MTS Securities, LLC, an affiliate of MTS Health Partners, L.P., served as financial advisor to NuPathe.
CONSHOHOCKEN, PA — (Marketwire) — August 6, 2010 — NuPathe Inc. (NASDAQ: PATH), a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders, today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at $10.00 per share, before underwriting discounts and commissions. All of the common stock is being offered by NuPathe. The shares are expected to begin trading on the NASDAQ Global Market under the symbol “PATH” today, August 6, 2010. In addition, the underwriters have a 30-day option to purchase up to an additional 750,000 shares of common stock from NuPathe to cover over-allotments, if any.
Leerink Swann LLC and Lazard Capital Markets LLC are acting as joint book-running managers for the offering. Needham & Company, LLC is acting as co-manager.
The transaction is scheduled to close on August 11, 2010, subject to the terms and conditions of the underwriting agreement.
A copy of the prospectus relating to the offering may be obtained by contacting Leerink Swann LLC, 37th Floor, One Federal Street, Boston, MA 02110, Attn: Syndicate Department, or Lazard Capital Markets LLC, 30 Rockefeller Plaza, 60th Floor, New York, NY 10020, or by calling (800) 542-0970.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on August 5, 2010. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
NuPathe Inc. is a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders. NuPathe’s most advanced product candidate, Zelrix™, is a transdermal patch for the treatment of migraine. Zelrix actively delivers sumatriptan, the most widely prescribed migraine medication, through the skin in a controlled manner using its proprietary SmartRelief™ technology.
In addition, NuPathe has two other proprietary product candidates in preclinical development that address large market opportunities: NP201 for the continuous symptomatic treatment of Parkinson’s disease, and NP202 for the long-term treatment of schizophrenia and bipolar disorder.